AIM: To establish the uptake of contralateral risk reducing mastectomy in women informed of their risks and options at time of diagnosis of their primary unilateral breast cancer. METHODS: We have assessed the surgical choices of 70 women diagnosed with breast cancer <50 years as part of a family history surveillance program and fully informed about their contralateral risks and surgical options. We have compared this to women from other surgical clinics who were subsequently found to harbour a pathogenic BRCA1/2 mutation. RESULTS: Sixty-five percent (13/20) of BRCA1/2 mutation carriers and 59% (n=20/34) of those at the highest level of risk pre-diagnosis (33+% lifetime risk) opted for contra-lateral mastectomy in the study sample. In contrast only 10% (n=9/88) women identified as mutation carriers from other clinics opted for such surgery. CONCLUSIONS: We would suggest that women with a significant family history and therefore a high contra-lateral breast cancer risk, should have these risks and management options discussed at the time of diagnosis of breast cancer.
AIM: To establish the uptake of contralateral risk reducing mastectomy in women informed of their risks and options at time of diagnosis of their primary unilateral breast cancer. METHODS: We have assessed the surgical choices of 70 women diagnosed with breast cancer <50 years as part of a family history surveillance program and fully informed about their contralateral risks and surgical options. We have compared this to women from other surgical clinics who were subsequently found to harbour a pathogenic BRCA1/2 mutation. RESULTS: Sixty-five percent (13/20) of BRCA1/2 mutation carriers and 59% (n=20/34) of those at the highest level of risk pre-diagnosis (33+% lifetime risk) opted for contra-lateral mastectomy in the study sample. In contrast only 10% (n=9/88) women identified as mutation carriers from other clinics opted for such surgery. CONCLUSIONS: We would suggest that women with a significant family history and therefore a high contra-lateral breast cancer risk, should have these risks and management options discussed at the time of diagnosis of breast cancer.
Authors: Sungmin Park; Jeong Eon Lee; Jai Min Ryu; Issac Kim; Soo Youn Bae; Se Kyung Lee; Jonghan Yu; Seok Won Kim; Seok Jin Nam Journal: World J Surg Date: 2018-05 Impact factor: 3.352
Authors: Marc D Schwartz; Beth N Peshkin; Claudine Isaacs; Shawna Willey; Heiddis B Valdimarsdottir; Rachel Nusbaum; Gillian Hooker; Suzanne O'Neill; Lina Jandorf; Scott P Kelly; Jessica Heinzmann; Aliza Zidell; Katia Khoury Journal: Breast Cancer Res Treat Date: 2018-04-02 Impact factor: 4.872
Authors: Marijke R Wevers; Margreet G E M Ausems; Senno Verhoef; Eveline M A Bleiker; Daniela E E Hahn; Frans B L Hogervorst; Rob B van der Luijt; Heiddis B Valdimarsdottir; Richard van Hillegersberg; Emiel J T H Rutgers; Neil K Aaronson Journal: BMC Cancer Date: 2011-01-10 Impact factor: 4.430
Authors: Bettina Meiser; Kathy Tucker; Michael Friedlander; Kristine Barlow-Stewart; Elizabeth Lobb; Christobel Saunders; Gillian Mitchell Journal: Breast Cancer Res Date: 2008-11-28 Impact factor: 6.466